Recent Updates
Recently added Catalysts
EPIX

FORM 51-102F3 MATERIAL CHANGE REPORT Item 1: Name and Address of Company ESSA Pharma Inc. ("ESSA" or the "Company") Suite 720, 999 West Broadway Vancouver, British Columbia, Canada V5Z 1K5 Item 2: Date of Material Change

Key Takeaway: MATERIAL CHANGE REPORT Item 1: Name and Address of Company ESSA Pharma Inc. ("ESSA" or the "Company") Suite 720, 999 West Broadway Vancouver, British Columbia, Canada V5Z 1K5 Item 2: Date of Material Change Item 3: News Release A news release announcing the material chang

Full Press Release Details

MATERIAL CHANGE REPORT
Item 1: Name and Address of Company
ESSA Pharma Inc. ("ESSA" or the "Company")
Suite 720, 999 West Broadway
Vancouver, British Columbia, Canada V5Z 1K5
Item 2: Date of Material Change
Item 3: News Release
A news release announcing the
material change was issued on January 7, 2016 through Canada NewsWire and a copy was filed on SEDAR on January 7, 2016.
Item 4: Summary of Material Change
ESSA announced that Dr. David
Parkinson had been appointed as the company's President and Chief Executive Officer effective immediately, replacing Mr.
Bob Rieder who had announced his departure from the company and resignation from the Board of Directors.
Item 5: Full Description of Material Change
5.1 Full Description of Material Change
ESSA announced that Dr. David
Parkinson had been appointed as the company's President and Chief Executive Officer effective immediately, replacing Mr.
Bob Rieder who had announced his departure from the company and resignation from the Board of Directors. Prior to January 7, 2016,
Dr. Parkinson had been serving as a Director of the Company and he will continue acting in that capacity.
5.2 Disclosure for Restructuring Transactions
Item 6: Reliance on subsection 7.1(2) of National Instrument
Item 7: Omitted Information
Item 8: Executive Officer
For further information, please contact David Wood, CFO
of the Company at 778-331-0962.
Item 9: Date of Report
Last updated: May 25, 2018